Author

J. Decock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Naik· 2 shared D. Bedognetti· 2 shared G. Zoppoli· 2 shared W. Hendrickx· 2 shared A. Awad· 1 shared A. Jabeen· 1 shared A. Sanchez· 1 shared C. M. Raynaud· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Naik

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Modulation of SLFN11 induces changes in DNA Damage response

C. M. Raynaud, E. I. Ahmed, A. Jabeen, A. Sanchez, S. Sherif, T. C. Carneiro-Lobo, A. Awad, D. Awartani, A. Naik, R. Thomas, J. Decock, G. Zoppoli, D. Bedognetti, W. Hendrickx

This study shows that increasing SLFN11 expression through CRISPR-dCas9 systems enhances DNA damage response sensitivity in breast cancer cells.

bioRxiv · Apr 2, 2023 · PreprintCancer Biology

Targeting LDHC dysregulates the cell cycle and improves sensitivity to cisplatin and olaparib

A. Naik, J. Decock

This study shows that targeting LDHC disrupts the cell cycle and enhances sensitivity to cisplatin and olaparib in breast cancer cells.

bioRxiv · Mar 3, 2021Cancer Biology

Genomic landscape of tumor-host interactions with differential prognostic and predictive connotations

J. Roelands, W. Hendrickx, P. J. K. Kuppen, R. Mall, G. Zoppoli, M. Saad, K. Halliwill, G. Curigliano, D. Rinchai, J. Decock, L. Delogu, T. Turan, J. Samayoa, L. Chouchane, E. Wang, , D. Bedognetti

The paper analyzes tumor-host interactions across 31 cancer types using the ICR signature to identify prognostic and predictive implications of immune phenotypes.

bioRxiv · May 8, 2019Cancer Biology